2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Sugiura T and Waku K Cannabinoid receptors and their endogenous ligands. 2002 J. Biochem. pmid:12097154
Jordà MA et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. 2002 Blood pmid:11929767
Vannacci A et al. Down-regulation by cannabinoids of the immunological activation of human basophils and guinea pig mast cells. 2002 Inflamm. Res. pmid:12013387
Kirkham TC et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. 2002 Br. J. Pharmacol. pmid:12055133
Kreitzer AC and Regehr WG Retrograde signaling by endocannabinoids. 2002 Curr. Opin. Neurobiol. pmid:12049940
Nakane S et al. 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. 2002 Arch. Biochem. Biophys. pmid:12051682
Maccarrone M et al. Endocannabinoid degradation, endotoxic shock and inflammation. 2002 Curr Drug Targets Inflamm Allergy pmid:14561206
Laine K et al. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. 2002 Invest. Ophthalmol. Vis. Sci. pmid:12356827
Darmani NA The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. 2002 J. Pharmacol. Exp. Ther. pmid:11752094
González S et al. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. 2002 Brain Res. pmid:12393235
Rouzer CA et al. Chemical stability of 2-arachidonylglycerol under biological conditions. 2002 Chem. Phys. Lipids pmid:12270674
Bisogno T et al. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. 2002 Curr. Pharm. Des. pmid:11945157
Lichtman AH et al. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. 2002 J. Pharmacol. Exp. Ther. pmid:12065702
Dinh TP et al. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. 2002 Chem. Phys. Lipids pmid:12505697
Kojima S et al. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. 2002 Eur. J. Pharmacol. pmid:12063081
Razdan RK and Mahadevan A Recent advances in the synthesis of endocannabinoid related ligands. 2002 Chem. Phys. Lipids pmid:12505687
Kunos G et al. The quest for a vascular endothelial cannabinoid receptor. 2002 Chem. Phys. Lipids pmid:12505689
Schmid HH et al. Cell signaling by endocannabinoids and their congeners: questions of selectivity and other challenges. 2002 Chem. Phys. Lipids pmid:12505695
Kozak KR et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. 2002 J. Biol. Chem. pmid:12244105
van der Stelt M et al. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. 2002 J. Med. Chem. pmid:12166944
Mechoulam R et al. Cannabinoids and brain injury: therapeutic implications. 2002 Trends Mol Med pmid:11815270
Dinh TP et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. 2002 Proc. Natl. Acad. Sci. U.S.A. pmid:12136125
Matias I et al. Presence and regulation of the endocannabinoid system in human dendritic cells. 2002 Eur. J. Biochem. pmid:12153574
Gubellini P et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. 2002 J. Neurosci. pmid:12177188
Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. 2002 Brain Res. Mol. Brain Res. pmid:12008024
Kozak KR et al. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. 2002 J. Biol. Chem. pmid:11956198
Sugiura T et al. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. 2002 Feb-Mar Prostaglandins Leukot. Essent. Fatty Acids pmid:12052034
Fowler CJ and Jacobsson SO Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development? 2002 Feb-Mar Prostaglandins Leukot. Essent. Fatty Acids pmid:12052035
Högestätt ED and Zygmunt PM Cardiovascular pharmacology of anandamide. 2002 Feb-Mar Prostaglandins Leukot. Essent. Fatty Acids pmid:12052048
van der Stelt M et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. 2002 Oct-Dec Mol. Neurobiol. pmid:12428763
Jordà MA et al. The peripheral cannabinoid receptor Cb2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. 2003 Blood pmid:12406867
Viganò D et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. 2003 Neuropsychopharmacology pmid:12637958
Oka S et al. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. 2003 J. Neurochem. pmid:12787057
Jorda MA et al. Identification, characterization, and function of a novel oncogene: the peripheral cannabinoid receptor Cb2. 2003 Ann. N. Y. Acad. Sci. pmid:12799277
Walter L and Stella N Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes. 2003 Glia pmid:12951660
Wallace MJ et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. 2003 J. Pharmacol. Exp. Ther. pmid:12954810
Vannacci A et al. Nitric oxide modulates the inhibitory effect of cannabinoids on the immunological activation of guinea pig mast cells. 2003 Inflamm. Res. pmid:12755386
Kishimoto S et al. 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. 2003 J. Biol. Chem. pmid:12711605
Maccarrone M et al. Activation of human platelets by 2-arachidonoylglycerol is enhanced by serotonin. 2003 Thromb. Haemost. pmid:12574815
Walter L et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. 2003 J. Neurosci. pmid:12598628
Fride E et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. 2003 Eur. J. Pharmacol. pmid:12568912
Fowler CJ et al. Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. 2003 Biochem. Pharmacol. pmid:12948856
Patel S et al. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. 2003 J. Pharmacol. Exp. Ther. pmid:12808005
Watanabe S et al. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12878451
Hanus L et al. Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. 2003 Brain Res. pmid:12914975
Obata T et al. Simultaneous determination of endocannabinoids (arachidonylethanolamide and 2-arachidonylglycerol) and isoprostane (8-epiprostaglandin F2alpha) by gas chromatography-mass spectrometry-selected ion monitoring for medical samples. 2003 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:12829006
Maccarrone M et al. Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. 2003 J. Biol. Chem. pmid:12799380
Franklin A et al. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. 2003 J. Neurosci. pmid:12944505
Liu J et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. 2003 J. Biol. Chem. pmid:12949078
Derkinderen P et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. 2003 J. Neurosci. pmid:12657697
Gaetani S et al. Anandamide hydrolysis: a new target for anti-anxiety drugs? 2003 Trends Mol Med pmid:14604824
Maccarrone M et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. 2003 J. Neurochem. pmid:12716433
Lépicier P et al. Endocannabinoids protect the rat isolated heart against ischaemia. 2003 Br. J. Pharmacol. pmid:12813004
Bouchard JF et al. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. 2003 Life Sci. pmid:12586223
McCarron RM et al. Antioxidant properties of the vasoactive endocannabinoid, 2-arachidonoyl glycerol (2-AG). 2003 Acta Neurochir. Suppl. pmid:14753451
Higgs S et al. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. 2003 Psychopharmacology (Berl.) pmid:12447606
Bisogno T et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. 2003 J. Cell Biol. pmid:14610053
Facchinetti F et al. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. 2003 Glia pmid:12509806
Mechoulam R and Lichtman AH Neuroscience. Stout guards of the central nervous system. 2003 Science pmid:14526067
Marsicano G et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. 2003 Science pmid:14526074
Kim J and Alger BE Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. 2004 Nat. Neurosci. pmid:15184902
Witting A et al. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. 2004 J. Neurochem. pmid:15189359
Stanke-Labesque F et al. 2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products. 2004 Cardiovasc. Res. pmid:15194472
Oka S et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. 2004 J. Leukoc. Biol. pmid:15316028
Nithipatikom K et al. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. 2004 Cancer Res. pmid:15604240
González S et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. 2004 Drug Alcohol Depend pmid:15099659
Valenti M et al. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. 2004 Cell. Mol. Life Sci. pmid:15095014
Kishimoto S et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. 2004 J. Biochem. pmid:15115777
Hájos N et al. Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. 2004 Eur. J. Neurosci. pmid:15182306
Vannacci A et al. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. 2004 J. Pharmacol. Exp. Ther. pmid:15187170
Maestroni GJ The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. 2004 FASEB J. pmid:15385435
Walter L et al. ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. 2004 J. Neurosci. pmid:15371507
Dinh TP et al. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. 2004 Mol. Pharmacol. pmid:15272052
Malorni W et al. Morphological evidence that 2-arachidonoylglycerol is a true agonist of human platelets. 2004 Thromb. Haemost. pmid:15543349
Melis M et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. 2004 J. Neurosci. pmid:15564588
Sugiura T et al. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. 2004 J. Pharmacol. Sci. pmid:15599096
Saario SM et al. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. 2004 Biochem. Pharmacol. pmid:15013854
Alberich Jordà M et al. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. 2004 Blood pmid:15039279
Witting A et al. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. 2004 Proc. Natl. Acad. Sci. U.S.A. pmid:14976257
Carrier EJ et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. 2004 Mol. Pharmacol. pmid:15044630
Golech SA et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. 2004 Brain Res. Mol. Brain Res. pmid:15548432
Mukherjee S et al. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. 2004 Eur. J. Pharmacol. pmid:15556131
Guo J and Ikeda SR Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. 2004 Mol. Pharmacol. pmid:14978245
Piomelli D The endogenous cannabinoid system and the treatment of marijuana dependence. 2004 Neuropharmacology pmid:15464150
Ghafouri N et al. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. 2004 Br. J. Pharmacol. pmid:15492019
Motobe T et al. Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome. 2004 Shock pmid:14676677
van der Stelt M et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. 2005 FASEB J. pmid:15894565
Venderova K et al. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. 2005 Exp. Neurol. pmid:15899265
Julien B et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. 2005 Gastroenterology pmid:15765409
Chen J et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. 2005 Biochem. Biophys. Res. Commun. pmid:15823551
Sipe JC et al. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. 2005 J. Leukoc. Biol. pmid:15845647
Jung KM et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. 2005 Mol. Pharmacol. pmid:16051747
Makara JK et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. 2005 Nat. Neurosci. pmid:16116451
Secko D Analgesia through endogenous cannabinoids. 2005 CMAJ pmid:16103504
Maejima T et al. Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. 2005 J. Neurosci. pmid:16033892
Panikashvili D et al. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. 2005 J. Cereb. Blood Flow Metab. pmid:15729296
Gauthier KM et al. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:15528233
Gabbay E et al. Endocannabinoids and liver disease--review. 2005 Liver Int. pmid:16162147
Vandevoorde S et al. Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. 2005 Biochem. Biophys. Res. Commun. pmid:16181610
Ramos JA et al. Therapeutic potential of the endocannabinoid system in the brain. 2005 Mini Rev Med Chem pmid:16026307